TPP-45142

TPP-45142: sourced facts only. name: "Therefore, in this study, we developed a NANOBODY domain-based HER2-targeting, T-cell receptor αβ-based T-cell engager (TCE) molecule-TPP-45142; it recognizes a HER2 epitope distinct from that recognized by trastuzumab and pertuzumab and redirects T cells to kill HER2-low cancers such as breast, gastric, and gastroesophageal junction adenocarcinoma cancers." [PMID:41504346]; target: "Therefore, in this study, we developed a NANOBODY domain-based HER2-targeting, T-cell receptor αβ-based T-cell engager (TCE) molecule-TPP-45142; it recognizes a HER2 epitope distinct from that recognized by trastuzumab and pertuzumab and redirects T cells to kill HER2-low cancers such as breast, gastric, and gastroesophageal junction adenocarcinoma cancers." [PMID:41504346]; developer: "NANOBODY Research Platform, Sanofi, Ghent, Belgium." [PMID:41504346]; stage: "TPP-45142 mediated potent T cell-dependent cytotoxicity against HER2-low cancer cell lines in vitro and inhibited in vivo tumor growth of HER2-low breast cancer xenografts." [PMID:41504346]